it's either to get a synergy or to balance out some negatives, i'm never really sure with Area. he's banned anyways, so yeah.
it shouldn't really be necessary. mono-therapy produces enough of an anti-anhedonic effect, e.g. dopamine agonist prampiprexole[1] and ketamine[2], the latter also being a unique NMDA antagonist
Dopamine–prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity
https://www.ncbi.nlm...les/PMC4872408/
Beta-adrenergic stimulation of prolactin release from superfused pituitary cell aggregates.
https://www.ncbi.nlm.../pubmed/6282573
l-Isoproterenol (l-ISO), a specific agonist of beta-adrenergic receptors, evoked a prompt rise of prolactin (PRL) release from superfused anterior pituitary cell aggregates established in culture for 5 days. The effect was concentration-dependent between 1 and 100 nM. d-Isoproterenol was more than 2 orders of magnitude weaker than the l-isomer. When dopamine receptors were blocked with domperidone, PRL secretion was also stimulated by l-epinephrine (E) and l-norepinephrine (NE), the rank order of potency being l-ISO greater than E much greater than NE. Under the latter conditions dopamine and the alpha-adrenergic agonists, clonidine and phenylephrine, had no stimulatory effect at 1 microM. Stimulation of PRL release by l-ISO and E was blocked by the beta-receptor antagonist, propranolol, but not by the alpha-receptor blocker, prazosin.